WHO on Remdesiver vaccine disappointment – looking at alternatives to trial

More from the WHO:
  • says solidarity therapeutics trial produces conclusive evidence on effectiveness of repurposed drugs for covid-19 in record time
  • says interim remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality
  • who-interim results in trial indicate remdesivir appeared to have little or no effect on 28day mortality or in-hospital course of covid-19 in patients
  • study, which spans over 30 countries, looked at effects of treatments on overall mortality, initiation of ventilation, duration of hospital stay
  • newer antiviral drugs, immunomodulators and anti-sars cov-2 monoclonal antibodies are now being considered for evaluation at solidarity trial

Headlines via Reuters

Go to top